EU regulator backs Sanofi's injectable version of blood cancer drug [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Here are the details from the company's statement: * EMA's positive opinion for Sanofi's drug Sarclisa was onthe basis of late-stage trials ?which showed ?the subcutaneousversion demonstrated non-inferiority compared with theintravenous formulation. * Sarclisa was first approved ?in the EU in 2020 for treatingmultiple myeloma, a rare blood cancer that starts in ?the bonemarrow, ?where abnormal white ?blood cells multiply ?uncontrollablyand produce faulty proteins. * If approved in its new formulation, the drug would beadministered via an injector worn on the skin to deliver themedication over time. * Sanofi said the ?European Commission, which usually followsthe ?EMA's recommendation, is expected ?to make a ?final decisionin the coming months. * ?Sarclisa brought in 588 million ?euros ($677.14 million) ?insales in 2025. * The U.S. Food and Drug Administration is also reviewingthe company's application ?for the ?subcutaneous on-body injectorversion of the drug. * ($1 = 0.8684 ?euros
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed [MSNBC.com]MSNBC.com
- Novo's FDA voucher victory; biotech's rigid glass ceiling [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myelomaGlobeNewswire
- Sanofi (SNY) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".MarketBeat
- Sanofi Autoimmune Pipeline Grows As Market Weighs Valuation And Momentum [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 3/24/26 - Form 6-K
- 3/10/26 - Form 6-K
- 3/4/26 - Form 6-K
- SNY's page on the SEC website